- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07722741
Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC (IMPACT31)
IMPACT31: A Randomized Open-label, Multi-center, Phase II Adjuvant Study of a Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Plasmid Encoded IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC
This is a randomized, open-label, multi-site Phase II study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report, who were eligible to undergo definitive resection, have demonstrated laboratory, radiographic and/or pathologic high-risk criteria for recurrence (described under eligibility), have no evidence of disease (NED) as per MRI approximately 28 days post resection, and are able to provide a tissue sample for personalized neoantigen DNA vaccine development.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Joann Peters, MHA
- Número de teléfono: 434-825-2551
- Correo electrónico: peters@geneostx.com
Ubicaciones de estudio
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Aún no reclutando
- Emory University
-
Contacto:
- Principal Investigator, MD
- Número de teléfono: 404-251-1278
- Correo electrónico: kathleen.marie.coleman@emory.edu
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70112
- Reclutamiento
- Louisiana State University Health Sciences Center
-
Contacto:
- Principal Investigator, MD
- Número de teléfono: 504-568-4750
- Correo electrónico: omoave@lsuhsc.edu
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Reclutamiento
- Johns Hopkins University
-
Contacto:
- Principal Investigator, MD
- Número de teléfono: 410-955-8893
- Correo electrónico: GIClinicalTrials@jh.edu
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Aún no reclutando
- University of Michigan
-
Contacto:
- Principal Investigator, MD
- Número de teléfono: 734-936-8643
- Correo electrónico: ndparikh@med.umich.edu
-
-
New York
-
New York, New York, Estados Unidos, 10029
- Reclutamiento
- Icahn School of Medicine at Mount Sinai
-
Contacto:
- Principal Investigator, MD
- Número de teléfono: 212-241-7840
- Correo electrónico: denise.rodriguez3@mssm.edu
-
New York, New York, Estados Unidos, 10027
- Aún no reclutando
- New York Presbyterian Hospital-Columbia University Irving Medical Center
-
Contacto:
- Principal Investigator, MD
- Número de teléfono: 212-342-5162
- Correo electrónico: Cancerclinicaltrials@cumc.columbia.edu
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Aún no reclutando
- MD Anderson Cancer Center
-
Contacto:
- Principal Investigator, MD
- Número de teléfono: 713-792-2828
- Correo electrónico: GIClinicalTrials@mdanderson.org
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109
- Aún no reclutando
- Fred Hutchinson Cancer Center
-
Contacto:
- Principal Investigator, MD
- Número de teléfono: 206-667-1392
- Correo electrónico: giresearch@fredhutch.org
-
-
-
-
-
Auckland, Nueva Zelanda, 1023
- Reclutamiento
- Auckland City Hospital (Te Toka Tumai)
-
Contacto:
- Principal Investigator, MD
- Número de teléfono: 22932 64 0800 488 434
- Correo electrónico: LiverResearchUnit@adhb.govt.nz
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Written informed consent
- ≥18 years of age
- Histologically or cytologically confirmed diagnosis of HCC (not accepted: fibrolamellar, sarcomatoid, mixed cholangiocarcinoma)
- Child-Pugh Class A liver score
- Documented virology status of hepatitis
- Availability of a representative post-resection tumor tissue sample
- ECOG performance status of 0 or 1
- Adequate organ function
- Women of childbearing potential (WOCBP) and men must be willing to use an adequate method of contraception
Exclusion Criteria:
- Is currently participating in and receiving study drug or has participated in a study of an investigational agent and received study drug or used an investigation device, within 4 weeks to baseline
- Evidence of residual, recurrent, or metastatic disease at randomization
- Active or history of autoimmune disease or immune deficiency
- Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug
- Diagnosed additional malignancy within 5 years prior to baseline, except for: (a) non-invasive carcinomas subject to successful curative treatment in the opinion of the investigator which require no further therapy and (b) other malignancies for which subjects have undergone potentially curative therapy and have been considered disease free for at least 3 years prior to screening.
- Active infection requiring systemic therapy
- Is pregnant, breastfeeding or expecting to conceive or father children within the study's projected duration
- History of human immunodeficiency virus (HIV) (HIV I/II antibodies).
- Co-infection with HBV and hepatitis D viral infection
- Co-infection with HBV and HCV
- Has received a live vaccine within 30 days of planned start of study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Personalized Immunotherapy for Cancer:
GNOS-PV02 + INO-9012 ID followed by electroporation every 3 weeks for 4 doses, then every 9 weeks (Q9W) until week 104, then every 12 weeks (Q12W) until week 260 followed by 3 years follow-up survival |
delivered by intradermal injection and electroporation GNOS-PV02 + INO-9012 ID followed by electroporation cytokine interleukin-12 (IL-12), a vaccine adjuvant |
|
Sin intervención: Standard of Care
Active Surveillance for 5 years or until recurrence, plus 3 years follow-up survival. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Recurrence-free survival
Periodo de tiempo: Up to 5 years
|
RFS is defined as the time from randomization to any recurrence (local, locoregional, regional or distant), occurrence of new primary HCC, as assessed by the investigator, or death due to any cause, whichever occurs first. |
Up to 5 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of treatment emergent adverse events (safety and tolerability)
Periodo de tiempo: Up to 5 years
|
Summary adverse events according to CTCAE 6.0 |
Up to 5 years
|
|
Time to extra-hepatic spread or macro-vascular invasion
Periodo de tiempo: Up to 5 years
|
Time to extra-hepatic spread or macro-vascular invasion (TTEHS/MVI) |
Up to 5 years
|
|
Overall survival
Periodo de tiempo: Up to 5 years on study + 3 years follow up
|
OS is defined as time from randomization to death of any cause |
Up to 5 years on study + 3 years follow up
|
|
RFS rate at 12, 18 and 24 months as assessed by the investigator
Periodo de tiempo: Randomization up to 12 months, 18 and 24 months
|
The proportion of patients who remain free from disease recurrence after treatment over a specified period |
Randomization up to 12 months, 18 and 24 months
|
|
RFS rate at 12, 18 and 24 months as assessed by the BIRC
Periodo de tiempo: Randomization up to 12 months, 18 months and 24 months
|
The proportion of patients who remain free from disease recurrence after treatment over a specified period |
Randomization up to 12 months, 18 months and 24 months
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- GT-31
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
At the time of registration, the sponsor has not yet determined whether de-identified individual participant data collected during the study will be shared. A decision regarding data sharing will be made following study completion and in accordance with sponsor policies, applicable regulations, and ethical considerations.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .